BTEK.L vs. KURE.L

Last updated Jun 5, 2026

BTEK.L (iShares Nasdaq US Biotechnology UCITS ETF) and KURE.L (KraneShares MSCI All China Health Care Index UCITS ETF USD) are both Health & Biotech Equities funds - BTEK.L tracks the NASDAQ Biotechnology TR USD while KURE.L tracks the MSCI World/Health Care NR USD. Both are passively managed. Over the past year, BTEK.L returned 43.15% vs -10.03% for KURE.L. At a 0.28 correlation, their price movements are largely independent. BTEK.L charges 0.35%/yr vs 0.65%/yr for KURE.L.

Performance

BTEK.L vs. KURE.L - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) and KraneShares MSCI All China Health Care Index UCITS ETF USD (KURE.L). The values are adjusted to include any dividend payments, if applicable.

Different Trading Currencies

BTEK.L is traded in GBP, while KURE.L is traded in USD. To make them comparable, the KURE.L values have been converted to GBP using the latest available exchange rates.

Returns By Period

In the year-to-date period, BTEK.L achieves a 4.86% return, which is significantly higher than KURE.L's -10.32% return.

BTEK.L

• 1D: 3.56%
• 1M: 2.25%
• YTD: 4.86%
• 6M: 2.70%
• 1Y: 43.15%
• 3Y*: 10.19%
• 5Y*: 5.85%
• 10Y*: —

KURE.L

• 1D: -2.53%
• 1M: -11.57%
• YTD: -10.32%
• 6M: -20.07%
• 1Y: -10.03%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

BTEK.L vs. KURE.L - Yearly Performance Comparison

	2026 (YTD)	2025
BTEK.L iShares Nasdaq US Biotechnology UCITS ETF	4.86%	36.67%
KURE.L KraneShares MSCI All China Health Care Index UCITS ETF USD	-10.32%	11.24%

Correlation

The correlation between BTEK.L and KURE.L is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.26
Correlation (All Time) Calculated using the full available price history since Apr 29, 2025	0.28

BTEK.L vs. KURE.L - Sectors Allocation Comparison

Sectors	BTEK.L	KURE.L
Healthcare	100.0%	98.3%
Basic Materials	-	0.8%
Communication Services	-	0.0%
Consumer Cyclical	-	0.0%
Consumer Defensive	-	0.9%
Energy	-	0.0%
Financial Services	-	0.0%
Industrials	-	0.0%
Real Estate	-	0.0%
Technology	-	0.0%
Utilities	-	0.0%

Return for Risk

BTEK.L vs. KURE.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BTEK.L

BTEK.L Risk / Return Rank: 76
BTEK.L Sharpe Ratio Rank: 70
BTEK.L Sortino Ratio Rank: 70
BTEK.L Omega Ratio Rank: 63
BTEK.L Calmar Ratio Rank: 92
BTEK.L Martin Ratio Rank: 85

KURE.L

KURE.L Risk / Return Rank: 6
KURE.L Sharpe Ratio Rank: 6
KURE.L Sortino Ratio Rank: 6
KURE.L Omega Ratio Rank: 6
KURE.L Calmar Ratio Rank: 6
KURE.L Martin Ratio Rank: 6

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BTEK.L vs. KURE.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) and KraneShares MSCI All China Health Care Index UCITS ETF USD (KURE.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BTEK.L	KURE.L	Difference
Sharpe ratio: Return per unit of total volatility	2.24	-0.31	+2.55
Sortino ratio: Return per unit of downside risk	3.13	-0.25	+3.39
Omega ratio: Gain probability vs. loss probability	1.38	0.97	+0.41
Calmar ratio: Return relative to maximum drawdown	6.23	-0.27	+6.50
Martin ratio: Return relative to average drawdown	17.55	-0.56	+18.11
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BTEK.L vs. KURE.L - Sharpe Ratio Comparison

The current BTEK.L Sharpe Ratio is 2.24, which is higher than the KURE.L Sharpe Ratio of -0.31. The chart below compares the historical Sharpe Ratios of BTEK.L and KURE.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	BTEK.L	KURE.L	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.24	-0.31	+2.55
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.29	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.31	-0.01	+0.32

Drawdowns

BTEK.L vs. KURE.L - Drawdown Comparison

The maximum BTEK.L drawdown since its inception was -30.86%, roughly equal to the maximum KURE.L drawdown of -29.65%. Use the drawdown chart below to compare losses from any high point for BTEK.L and KURE.L.

Drawdown Indicators

	BTEK.L	KURE.L	Difference
Max Drawdown Largest peak-to-trough decline	-30.86%	-29.65%	-1.21%
Max Drawdown (1Y) Largest decline over 1 year	-6.89%	-29.65%	+22.76%
Max Drawdown (3Y) Largest decline over 3 years	-26.34%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-30.86%	—	—
Current Drawdown Current decline from peak	-1.86%	-29.65%	+27.79%
Average Drawdown Average peak-to-trough decline	-10.04%	-10.97%	+0.93%
Ulcer Index Depth and duration of drawdowns from previous peaks	2.45%	14.42%	-11.97%

Volatility

BTEK.L vs. KURE.L - Volatility Comparison

iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) and KraneShares MSCI All China Health Care Index UCITS ETF USD (KURE.L) have volatilities of 6.91% and 6.97%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BTEK.L	KURE.L	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.91%	6.97%	-0.06%
Volatility (6M) Calculated over the trailing 6-month period	14.67%	17.88%	-3.21%
Volatility (1Y) Calculated over the trailing 1-year period	19.14%	26.43%	-7.29%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	20.08%	26.09%	-6.01%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	21.71%	26.09%	-4.38%

BTEK.L vs. KURE.L - Expense Ratio Comparison

BTEK.L has a 0.35% expense ratio, which is lower than KURE.L's 0.65% expense ratio.

Dividends

BTEK.L vs. KURE.L - Dividend Comparison

Neither BTEK.L nor KURE.L has paid dividends to shareholders.

Tickers have no history of dividend payments

Frequently Asked Questions

Can I hold both BTEK.L and KURE.L in my portfolio?

BTEK.L and KURE.L have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which ETF is better, BTEK.L or KURE.L?

On fees, BTEK.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, BTEK.L or KURE.L?

BTEK.L is cheaper with a 0.35% expense ratio, compared with 0.65% for KURE.L.

What is the main difference between BTEK.L and KURE.L?

BTEK.L tracks NASDAQ Biotechnology TR USD, while KURE.L tracks MSCI World/Health Care NR USD. They also come from different issuers: iShares and MLC Management. Their fees differ too: 0.35% for BTEK.L and 0.65% for KURE.L.